 SpringWorks Therapeutics Inc. NASDAQ: SWTX stock jumped 20 after the clinical-stage company focusing on life-changing treatment for cancer, and rare diseases announced encouraging results from its DeFi study. The trial was a placebo-controlled, double-blind third phase study assessing the safety, tolerability, and efficacy of the companys experimental oral gamma-secretase inhibitor, Nirogacestat, in the treatment of ... The post Here is why SpringWorks Therapeutics jumped 20 appeared first on Invezz. 